Dilon CEO Lori Chmura and Southeast Regional Sales Manager Tom Melba attended the 24th Annual Multidisciplinary Symposium on Breast Disease this past month to exhibit MarginProbe, the only FDA approved intraoperative tool for margin assessment.
Here are some of their favorite moments from the symposium.
Time to Treatment
Stephen R. Grobmyer, MD from the Cleveland Clinic gave an impressive presentation on Time to Treatment (TTT), the time from a new diagnosis of cancer to treatment initiation. This presentation explored the many lines of evidence suggesting that TTT is associated with breast cancer outcomes. The presentation also highlighted that time to adjuvant chemotherapy is increasing.
With re-excisions being one of the factors linked with delayed initiation of adjuvant chemotherapy, avoiding a second surgery could significantly improve patient outcomes. The use of MarginProbe during breast-conservation surgery to reduce the risk of re-excision and the implementation of other innovative multidisciplinary lean processes are just some ways to help lower TTT for breast cancer.
Risk Associated with Benign Breast Disease
Another presentation that caught their interest was “Risk Associated with Benign Breast Disease” by Amy C. Degnim, MD from the Mayo Clinic. This presentation categorized the risk of breast cancer for patients with atypical ductal hyperplasia, atypical lobular hyperplasia, and lobular carcinoma in situ – which is moderate to high. While these abnormal types of tissue are not true forms of breast cancer, they do increase your risk for breast cancer later on. The categorizing of these risk factors can help providers and patients choose the appropriate methods for surveillance and prevention of breast cancer.
Meeting with MarginProbe Users
Some of the MarginProbe users in attendance were Drs. Brackett and Mislowsky from Tidelands Health, Dr. Stephanie Akbari from Virginia Cancers Specialists, and Dr. James Pellicane from Bon Secours. Attendance at the symposium also facilitated the ability to meet with the Head of Surgical Oncology, Breast, Endocrine, Melanoma at the new Baptist MD Anderson center in Jacksonville.
Dilon appreciated the opportunity to connect with so many peers and gain new insights from such distinguished organizations. If you would like to know more about Dilon Devices and our RF spectroscopy technology platform, contact firstname.lastname@example.org today.